Again discussing that they needed a larger trial to say it was better than Eylea.
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-21
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
86.5¢ |
Change
-0.030(3.35%) |
Mkt cap ! $1.064B | |||
| Open | High | Low | Value | Volume |
| 88.5¢ | 88.5¢ | 85.8¢ | $1.890M | 2.181M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 25128 | 86.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 87.0¢ | 30613 | 14 |
View Market Depth
| Last trade - 13.22pm 08/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |